<DOC>
	<DOC>NCT00761462</DOC>
	<brief_summary>Objective and subjective musculoskeletal evaluations will be performed to determine differences in the ciprofloxacin versus non-quinolone treated pediatric patients so that we can tell what the natural occurrence of such musculoskeletal conditions is in the general pediatric population.</brief_summary>
	<brief_title>BAY 0 9867 Cipro Pediatric Use Study (QUIP)</brief_title>
	<detailed_description>This study is classified as "interventional" due to study-specific medical examinations and interventions. Regarding the study drug intake, routine administration is observed only, there is no intervention in study drug administration.</detailed_description>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<mesh_term>Antibiotics, Antitubercular</mesh_term>
	<criteria>Patient is &gt;/= 2 months of age through 16 years of age A parent/caregiver must sign an informed consent Patient must provide assent, as appropriate based on local institutional review board guidelines Patients presenting with the following conditions: exacerbations of cystic fibrosis (CF) meningitis Brain abscess bacterial endocarditis, Bone and joint infections having any of the following conditions but lacking a personal history may be admitted to the trial: Arthritis Juvenile rheumatoid arthritis (JRA) Rheumatoid arthritis (RA) Systemic lupus erythematosis (SLE) History of rheumatic fever Psoriasis Inflammatory bowel disease Osteoarthritis (OA) Known underlying rheumatological disease, joint problems known to be associated with arthropathy. Patients with any pretreatment baseline musculoskeletal exam abnormalities Known risk of experiencing seizures, a history of any convulsive disorders Requiring any concomitant therapeutic course of systemic antibacterial agent Participation in any industrysponsored clinical drug development study within one month prior to this study Known significant liver impairment (ALAT/ASAT and/or baseline bilirubin &gt; 3 times upper limit of normal) Known significant renal insufficiency (calculated creatinine clearance of &lt; 30 ml/min/1.73 mÂ²) Are pregnant or lactating, or are sexually active and using unreliable contraception.</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Pediatrics</keyword>
	<keyword>Safety</keyword>
	<keyword>Musculoskeletal System</keyword>
	<keyword>Neurologic Manifestations</keyword>
	<keyword>Joint Diseases</keyword>
	<keyword>Joint Deformities, Acquired</keyword>
</DOC>